Guru Sonpavde shared a post on LinkedIn:
”ESMO24 bladder cancer potentially practice-changing highlights from 2 key Phase III clinical trials on Doximity: Pleased to comment on NIAGARA (Neoadjuvant Gemcitabine-Cisplatin +/- peri-operative durvalumab for muscle-invasive bladder cancer) and AMBASSADOR (Adjuvant pembrolizumab vs observation for muscle-invasive bladder cancer) trials from AdventHealth Central Florida Cancer Institute, Orlando, Florida.”